Cancer patients get extended access to experimental drug in safety Follow-Up

NCT ID NCT04058756

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study allows 120 patients with advanced solid tumors who are already benefiting from the experimental immunotherapy drug spartalizumab to continue receiving it. The main goal is to monitor the drug's long-term safety and side effects. It is a follow-up for patients who participated in earlier Novartis-sponsored trials.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Columbia University Medical Center

New York, New York, 10032, United States
MD Anderson Cancer Center Uni of Te

Houston, Texas, 77030, United States
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Guangzhou, 510060, China
Novartis Investigative Site

Brno, 656 53, Czechia
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

High West, Hong Kong
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Pokfulam, 999077, Hong Kong
Novartis Investigative Site

Budapest, H 1122, Hungary
Novartis Investigative Site

Debrecen, 4032, Hungary
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Milan, MI, 20141, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Modena, MO, 41124, Italy
Novartis Investigative Site

Aviano, PN, 33081, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Leiden, South Holland, 2333 ZA, Netherlands
Novartis Investigative Site

Gdansk, 80-952, Poland
Novartis Investigative Site

Poznan, 60-693, Poland
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Songkhla, Hat Yai, 90110, Thailand
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Providence Portland Medical Center

Portland, Oregon, 97123, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS